Miguel A. Campos-Galindo
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer.
Journal: Frontiers in immunology
Published: February 02, 2026
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer.
Journal: Cell reports. Medicine
Published: August 28, 2024
Pre-existing tumor host immunity characterization in resected non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 21, 2022
Impact of DNA Damage Response-Targeted Therapies on the Immune Response to Tumours.
Journal: Cancers
Published: October 29, 2021
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
Journal: Blood
Published: June 07, 2021
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside.
Journal: Cancers
Published: August 13, 2019
Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promotes B-cell development and function.
Journal: Cell death and differentiation
Published: September 27, 2018
Understanding specific functions of PARP-2: new lessons for cancer therapy.
Journal: American journal of cancer research
Published: August 27, 2016
PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas.
PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas.
Journal: Scientific reports
Published: August 23, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026